MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma by �옣�씤�씡
Carcinogenesis vol.33 no.2 pp.294–300, 2012
doi:10.1093/carcin/bgr286
Advance Access publication December 9, 2011
MicroRNA-34a suppresses malignant transformation by targeting c-Myc
transcriptional complexes in human renal cell carcinoma
Soichiro Yamamura, Sharanjot Saini, Shahana Majid,
Hiroshi Hirata, Koji Ueno, Inik Chang, Yuichiro Tanaka,
Ashish Gupta and Rajvir Dahiya
Department of Urology, San Francisco Veterans Affairs Medical Center and
University of California, San Francisco, CA 94121, USA
To whom correspondence should be addressed. Urology Research Center
(112F), Veterans Affairs Medical Center and University of California, San
Francisco, 4150 Clement Street, San Francisco, CA 94121, USA.
Tel: 415-221-4810 Ex. 6964; Fax: 415-750-6639;
Email: rdahiya@urology.ucsf.edu
We investigated the functional effects of microRNA-34a (miR-
34a) on c-Myc transcriptional complexes in renal cell carcinoma.
miR-34a down-regulated expression of multiple oncogenes
including c-Myc by targeting its 3# untranslated region, which
was revealed by luciferase reporter assays. miR-34a was also
found to repress RhoA expression by suppressing the c-Myc–
Skp2–Miz1 transcriptional complex that activates RhoA. Over-
expression of c-Myc reversed miR-34a suppression of RhoA
expression and inhibition of cell invasion, suggesting that miR-
34a inhibits invasion by suppressing RhoA through c-Myc.
miR-34a was also found to repress the c-Myc–P-TEFb transcrip-
tion elongation complex, indicating one of the mechanisms by
which miR-34a has profound effects on cellular functions.
Our results demonstrate that miR-34a suppresses assembly
and function of the c-Myc complex that activates or elongates
transcription, indicating a novel role of miR-34a in the regula-
tion of transcription by c-Myc.
Introduction
MicroRNAs (miRNAs) are highly conserved, single stranded, non-
coding RNAs of 22 nucleotides that regulate gene expression by
posttranscriptional silencing of specific target messenger RNAs
(mRNAs) by repressing translation or cleaving RNA transcripts
(1). miRNAs regulate diverse cellular processes, such as cell-cycle
progression, proliferation apoptosis and development. miRNAs
have been shown to function as oncogenes or tumor suppressor
genes (2). p53 has been found to target the microRNA-34 (miR-
34) family (3–5) and the ectopic expression of miR-34 genes has
drastic effects on cell proliferation and survival. Ectopic miR-34a
causes cell-cycle arrest in the G1 phase (5,6), increased apoptosis
(6,7) and inhibits metastasis (8). It has also been suggested that
a positive feedback loop exists between p53 and miR-34a as
miR-34a activates p53 by inhibiting silent information regulator
1 (9). Implications of miR-34a in renal cancer suppression and
progression have been reported (10,11), however, no functional
study has been conducted.
The proto-oncogene c-Myc regulates cell proliferation and trans-
formation both transcriptionally and non-transcriptionally and is
frequently de-regulated in human cancers (12,13). c-Myc is a basic
helix–loop–helix and leucine zipper transcription factor, which
binds to Enhancer Box elements (E-boxes) and activates the tran-
scription of genes which stimulate cell-cycle progression and cell
growth. c-Myc was reported to activate MiR-17-92, a polycistronic
miRNA cluster consisting of miR-17, -18a, -19a, -20a, -19b and -92a
(14,15). miR-19 was found to be the principal oncogenic component
of this cluster, targeting the tumor suppressor (16). miR-34c has
been shown to negatively regulate c-Myc in response to DNA
damage and to inhibit c-Myc-induced DNA synthesis (17). During
oncogene-induced senescence, miR-34a was also found to target
c-Myc (18).
Rho GTPases are small G proteins that regulate various cellular
processes, including cytoskeletal dynamics, migration, vesicle traf-
ficking, cell proliferation, apoptosis and transcription (19–21). Rho
GTPases, their regulators and their effectors have been suggested
to control tumor formation and progression. RhoA has been found
to control cancer metastasis and progression (22–24). Recently, the
c-Myc–Skp2–Miz1 complex was shown to activate the RhoA gene
(25).
The positive transcription elongation factor b (P-TEFb) regulates
the promoter-proximal pause release of the elongation phase of tran-
scription by RNA polymerase II (Pol II) (26) and integrates mRNA
synthesis with histone modification, pre-mRNA processing and
mRNA export (27). P-TEFb is composed of cyclin (CycT1, CycT2a,
CycT2b or CycK) and cyclin-dependent kinase 9 (Cdk9) (26). c-Myc
interacts with cyclin T1 (CycT1), the regulatory component of
P-TEFb and controls the elongation phase of transcription of Pol II
(28–30).
We report here the effects of miR-34a on the two c-Myc transcrip-
tional complexes. Via targeting c-Myc, miR-34a reduced the c-Myc–
Miz–Skp2 complex, which induces RhoA transcription and inhibited
cell invasion, showing miR-34a indirectly regulates RhoA. miR-34a
also suppressed c-Myc–P-TEFb complex that plays a key role in
controlling the elongation phase of transcription by Pol II, indicating
one of mechanisms by which miR-34a has dramatic effects on cellular
function. Our results demonstrate that miR-34a directly suppresses
formation and function of the c-Myc complex that activates or elon-
gates transcription, revealing a novel role of miR-34a in the regulation
of transcription by c-Myc.
Materials and methods
Cell culture and transfection
Human renal carcinoma cells, A498 [primary renal cell carcinoma (RCC)]
and 769P cells were purchased from The American Type Culture Collection
(Manassas, VA). A498 and 769P cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum.
Cells in six-well plates were transfected with 30 nM pre-miR negative
control (NC) or pre-miR-34a (Applied Biosystems, Foster City, CA)
using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s
instructions.
Transwell invasion assay
A498 or 769P cells were grown in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum. Culture inserts of 8 lm pore size
(Transwell; Costar) were coated with Matrigel (BD Biosciences, San
Jose, CA) (100 lg per well) and placed into the wells of 24-well culture
plates. In the lower chamber, 500 ll of Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum was added and 1  105 cells
were seeded to the upper chamber. After 48 h of incubation at 37C with 5%
CO2, the number of cells that had migrated through the pores was fixed
with 10% formalin and stained with 0.05% Crystal Violet. Crystal Violet
was solubilized with methanol and absorbance at 540 nm was measured
by a kinetic microplate reader (Spectra MAX 190; Molecular Devices
Co., Sunnyvale, CA). Data are the mean ± standard deviation of three
independent experiments.
Abbreviations: CAD, carbamoyl-phosphate synthase/aspartate transcarba-
moylase/dihydroorotase; ChIP, chromatin immunoprecipitation; Cdk, cyclin-
dependent kinase; Cyc, cyclin; CycT1, cyclin T1; E-boxes, Enhancer Box
elements; IP, immunoprecipitation; mRNA, messenger RNA; miR; microRNA,
miRNA; microRNAs; miR-34a, microRNA-34a, NC; negative control, PCR;
polymerase chain reaction, P-TEFb; positive transcription elongation factor b,
Pol II; RNA polymerase II, RCC; renal cell carcinoma; UTR, untranslated
region.
 The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com 294
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RNA extraction and quantitative real-time PCR
RNAwas isolated using the RNeasy Mini kit (Qiagen, Valencia, CA) according
to the manufacturer’s instructions. Reverse transcription reactions were
performed using a Reverse Transcription System Kit (Promega, Madison,
WI). Quantitative real-time polymerase chain reaction (PCR) analysis was
performed in triplicate with an Applied Biosystems Prism7500 Fast Sequence
Detection System using TaqMan universal PCR master mix according to the
manufacturer’s protocol (Applied Biosystems). Levels of RNA expression
were determined using the 7500 Fast System SDS software version 1.3.1
(Applied Biosystems).
miRNA extraction and quantitative real-time PCR
Total RNAwas isolated using the miRNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions. Reverse transcription reactions were performed
using a Reverse Transcription System Kit (Applied Biosystems). Quantitative
real-time PCR analysis was performed as described above.
Plasmid construction
Putative target sites of the 3# untranslated region (UTR) were cloned into
the PmeI–XbaI site of the dual luciferase pmirGLO vector (Promega). For
mismatch constructs, six mismatches were introduced in the putative target
site.
A human c-Myc expression vector was constructed by subcloning the
full-length complementary DNA of c-Myc (Invitrogen, Carlsbad, CA) into
the HindIII–XhoI site of the pCMV6-ENTRY vector (Origene).
Generation of stable miR-34a cell lines
HIV-based lentiviral packaging system including a plasmid expressing
miR-34a or vector control was purchased from GeneCopoeia (Rockville,
MD). A498 cells were infected with the HIV-based lentivirus expressing
miR-34a or vector control, and the infected A498 cells were selected with
puroc-Mycine.
Western blot
Protein extracts were resolved by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and transferred to polyvinylidene fluoride membranes
(Hybond-P; GE Healthcare, Piscataway, NJ), followed by incubation with
the indicated primary and secondary antibodies conjugated to horseradish
peroxidise (GE Healthcare). Signals were detected using the enhanced
chemiluminescence detection system (Amersham ECL plus Western
Blotting detection system, Fairfield, CT). Antibodies against c-Myc, RhoA,
Skp2 and GAPDH were purchased from Cell Signaling Technology
(Danvers, MA). Antibodies against Miz1, Max, Cdk9, ARHGEF3 and
ARHGEF18 were purchased from GeneTex Irvine, CA). Antibodies against
BCL2and CycT1 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). An antibody against Rock1 was purchased from BD
Biosciences.
Luciferase reporter assay
Cells in 24-well plates were transfected with 30 nM pre-miR NC or pre-miR-
34a (Applied Biosystems) using Lipofectamin 2000 (Invitrogen), according to
the manufacturer’s instructions. Transfections of plasmids were performed
using FuGENE HD (Roche Diagnosis, Basel, Switzerland) according to
the manufacturer’s instructions. Luciferase activity was assayed 48 h after
transfection, using a dual-luciferase reporter assay system (Promega).
All transfection experiments were performed in triplicate.
Chromatin immunoprecipitation
Chromatin immunoprecipitations (ChIPs) were performed using the Chroma-
tin Immunoprecipitation Assay Kit (Epigentek, Brooklyn, NY) according to
manufacturer’s instructions. DNA was sheared by sonication. A 1% portion of
the sheared DNA–protein complex was used for an input DNA sample. Anti-
bodies against c-Myc or Pol II (Millipore, Billerica, MA) or normal mouse/
rabbit IgG (Millipore) was used for immunoprecipitation (IP). Real-time PCR
quantitation of ChIP was performed in triplicate, normalized by input and
expressed as a fold increase over the control. Primers used for real-time
PCR were as follows: RhoA E-box5/6, 5#-CTTCGCGTGCGTGAA-
GAGTTG-3#and 5#-CATCCACTATTGCTCAGGAGC-3#; b-actin promoter,
5#-TCGATATCCACGTGACATCCA-3# and 5’-GCAGCATTTTTTTACCCC
CTC-3’.
Immunoprecipitation
Cells were lysed in buffer containing 250 mM NaCl, 50 mM N-2-hydroxye-
thylpiperazine-N#-2-ethanesulfonic acid, pH 7.5, 0.1% Nonidet P40, 5 mM
ethylenediaminetetraacetic acid and a protease inhibitor cocktail (Sigma–
Aldrich, St Louis, MO). Protein A/G–Sepharose beads (Santa Cruz Biotech-
nology) were added to the lysate for 60 min at 4C for preclearance. The
precleared lysate was incubated with an anti-c-Myc antibody (Cell Signaling
Technology) and protein A/G–Sepharose beads overnight at 4C. The protein
A/G–Sepharose beads were washed with the lysis buffer. The proteins were
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
analyzed by western blot.
Statistical analysis
Data are shown as mean values ± standard deviation. The Student’s t-test was
used to compare the two different groups. P values of ,0.05 were regarded as
statistically significant (n 5 3).
Results
miR-34a targets oncogenes
To study the target genes of miR-34a in RCCs, we transiently
transfected A498 and 769P cells with pre-miR NC or pre-miR-
34a. The transient transfection of pre-miR-34a increased miR-34a
levels in A498 and 769P cells (Supplementary Figure S1, available
at Carcinogenesis Online). Oncogenes, c-Met, c-Myc and BCL2,
have predicted binding sites for miR-34a in their 3# UTRs
(Supplementary Figure S2, available at Carcinogenesis Online).
c-Met has two predicted binding sites for miR-34a in its 3# UTR
(Supplementary Figure S2, available at Carcinogenesis Online).
We cloned the putative miR-34a targets in the 3# UTRs into
a luciferase construct. Luciferase reporter assays with miR-34a-
expressing A498 and 769P cells showed that miR-34a repressed
luciferase activity. Mutation of the putative miR-34a target sites in
these UTRs decreased the response to miR-34a. These results
indicate that miR-34a binds to the 3# UTRs of these genes
(Figure 1A).
Subsequently, we found that transfection of pre-miR-34a
reduced the protein levels of c-Met, c-Myc and BCL2 protein in
A498 and 769P cells (Figure 1B). The protein expression
levels were quantified and shown in Supplementary Figure S3,
available at Carcinogenesis Online. These results indicate that
miR-34a directly targets c-Met and c-Myc via binding to the 3#
UTRs in A498cells. miR-34a also reduced transcription factor
E2F1, which regulates the cell cycle, DNA replication and
cell proliferation (Figure 1B). Compared with the results of 3
#UTR reporter assays (Figure 1A), the reduction of the protein
level was significant, suggesting translational regulation. Other
signaling pathways on which miR-34a has effects also may reduce
c-Myc protein expression because miR-34a targets many genes.
Further studies are required to account for the differences in these
assays.
miR-34a inhibits A498 and 769P cell invasion
The c-Myc–Skp2–Miz1 transcriptional complex was found to
activate RhoA gene and to be critical for cell invasion and cancer
metastasis (25). Since we found that c-Myc is a target of miR-34a,
we studied effect of miR-34a on RhoA through the c-Myc–Skp2–
Miz1 transcriptional complex. We first performed a transwell
invasion assay using Matrigel to investigate the effect of miR-34a
on the invasion of A498 cells. We transiently transfected the cells
with pre-miR NC or pre-miR-34a and performed transwell invasion
assay. miR-34 reduced invasion to about 80% of that of NC in A498
cells (Figure 2). We also investigated the effect of miR-34a on the
invasion of 769P cells. miR-34a reduced invasion to only about 20%
of that of NC in 769P cells (Supplementary Figure S4, available at
Carcinogenesis Online).
miR-34a inhibits RhoA and suppresses assembly of the c-Myc
transcriptional complex
Since we found that miR-34a down-regulated the expression of
c-Myc by targeting its 3# UTR (Figure1), we examined whether
Targeting c-Myc transcriptional complexes in human renal cell carcinoma
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the down-regulation of c-Myc by miR-34a results in reduction
of RhoA expression through decreasing the assembly of the
c-Myc–Skp2–Miz1 complex. We observed a large-inhibition effect
of miR-34a on invasion in A498 cells, thus we used A498 cells
for further invasion study. Real-time PCR shows that miR-34a
decreased RhoA mRNA levels (Figure 3A) and western blot
revealed that miR-34a reduced RhoA protein expression
(Figure 3B).
We performed IP to study the assembly of c-Myc–Skp2–Miz1 tran-
scriptional complex in miR-34a-transfected cells. IP revealed that
endogenous c-Myc immunocomplex contained Miz1, Skp2 and
Max, indicating that c-Myc–Skp2–Miz1 complex was assembled in
A498 cells and miR-34a decreased these components in the c-Myc
immunocomplex (Figure 3C).
We performed ChIP assays to examine whether miR-34a reduces
binding of c-Myc to the RhoA promoter region of E-boxes 5 and 6,
which is a primary binding site of c-Myc (25). The ChIP assay
showed that endogenous c-Myc binds to E-boxes 5 and 6 and
miR-34a reduced the binding. Pol II bound to the b-actin promoter
was not altered in control experiments (Figure 3D). These
results suggested that miR-34a reduced the recruitment of
c-Myc–Skp2–Miz1 complex to the RhoA promoter reducing RhoA
expression.
Overexpression of c-Myc reverses inhibition of invasion
To examine whether inhibition of invasion by miR-34 could be
reversed via restoration of c-Myc levels, we transfected A498 cells
with c-Myc expressing plasmid together with pre-miR-34a. c-Myc
overexpression partially rescued RhoA expression (Figure 4A) and
miR-34-induced suppression of invasion (Figure 4B).
We also transfected a stable miR-34a A498 cell line with c-Myc
expressing plasmid. To express miR-34a stably, we employed
the HIV lentiviral system to infect A498 cells with the virus
Fig. 1. miR-34a targets oncogenes in A498 and 769P cells. (A) A498 or 769P cells were transfected with pre-miR NC or pre-miR-34a or pre-miR-con for 8 h,
followed by transfection with control reporter plasmids or 3# UTR plasmids for 48 h. 3# UTR reporter activity was measured with a luciferase assay and
normalized to activity of Renilla luciferase. P , 0.05 compared with control. (B) A498 or 769P cells were transfected with pre-miR NC or pre-miR-34a or
pre-miR-con for 72 h. Protein expression level was analyzed by western blot.
Fig. 2. miR-34a inhibits invasion of A498 cells. (A) A498 cells were
transfected with pre-miR NC or pre-miR-34a for 48 h. The cells were
harvested and subjected to transwell invasion assay. The values are
normalized to those of NC. P , 0.05 compared with control. (B)
Representative images of the invaded A498 cells.
S.Yamamura et al.
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expressing miR-34a or vector control and the infected cells were
selected with puromycin. The infection increased miR-34a levels
by 65-fold in A498 cells (Supplementary Figure S5, available at
Carcinogenesis Online). c-Myc overexpression also partially res-
cued RhoA expression and miR-34-induced suppression of invasion
in the stable miR-34a A498 cell line (Supplementary Figure S6,
available at Carcinogenesis Online). These results suggest that
miR-34a inhibits invasion at least partially via RhoA reduction by
targeting c-Myc.
miR-34a suppresses assembly of the c-Myc–P-TEFb complex
The P-TEFb plays a key role in controlling the elongation phase of
transcription by Pol II (26). It is a Cdk comprised of Cdk9 and Cyc.
c-Myc has been shown to interact with P-TEFb through CycT1 and
regulate transcription elongation (28–30). Since miR-34a targets c-
Myc, we performed IP to study the assembly of c-Myc–P-TEFb
transcription elongation complex in mir-34a-transfected A498 and
769P cells. IP revealed that endogenous c-Myc pulled down CycT1,
Cdk9 and Max and interacted with P-TEFb. miR-34a decreased the
presence of P-TEFb in the c-Myc immunocomplex in A498 and
769P cells (Figure 5A).
c-Myc has been shown to activate transcription of carbamoyl-
phosphate synthase/aspartate transcarbamoylase/dihydroorotase
(CAD), via recruitment of P-TEFb (28,31,32). We studied the effect
of miR-34a on the expression level of CAD with 5,6-di-chloro-1-b-
D-ribofuranosyl-bensimidazole that specifically suppresses expres-
sion of c-Myc-responsive CAD by inhibiting P-TEFb (32). We found
that miR-34a decreased CAD mRNA expression in A498 and 769P
cells, whereas 5,6-di-chloro-1-b-D-ribofuranosyl-bensimidazole
restored the expression (Figure 5B). These results indicate that
miR-34a repressed these genes by suppressing the c-Myc–P-TEFb
complex.
Discussion
In this study, we demonstrated the functional effects of miR-34a on
c-Myc transcriptional complexes in RCC. We showed that miR-34a
inhibited c-Myc by binding to its 3# UTR and subsequently
suppresses the assembly and function of the c-Myc–Skp2–Miz1
complex that activates RhoA and the c-Myc–P-TEFb complex that
elongates transcription of a variety of genes in RCC. Mutations of
c-Myc are found in various cancers and its de-regulated expression
causes the uncontrolled expression of many genes, some of which
regulate cell proliferation and results in tumor development
(33,34). Although Myc alone is not able to transform cells and
requires a co-operating oncogene, such as ras oncogene (35),
c-Myc is one of the major factors in tumor development. Thus,
inhibition of c-Myc is thought to be a significant function of
miR-34a. Our results also show that miR-34a strongly inhibits cell
proliferation, in vivo xenograft tumor growth and cell invasion,
indicating that miR-34a functions as a tumor suppressor in A498
and 769P cells.
Rho GTPases, a family of small G proteins, regulate intracellular
actin dynamics, including cell polarity, migration, vesicle trafficking,
cell proliferation, apoptosis and gene expression (20). RhoA, a mem-
ber of the Rho family of GTPases, is implicated in transformation and
metastasis. RhoA has been documented to be an important factor
associated with various human cancers (36).
Cross talk between c-Myc and RhoA has been documented.
Proteomic experiments have revealed that c-Myc controls the
activity of RhoA-dependent routes (37). Transcriptomal profiling
has revealed that c-Myc is important for Rho-mediated transfor-
mation (38). Ras activates Rho, which leads to activation of c-Myc
through phosphorylation (39). c-Myc also inhibits the RhoA/Rock-
dependent cytoskeleton (40). Existence of unknown pathways in
association between c-Myc and RhoA has been implicated. As
a transcription factor, c-Myc activates a variety of genes with its
partner protein, Max and with other proteins (12). The c-Myc–
Skp2–Miz1 transcriptional complex was shown to activate RhoA
and to be essential for cell invasion and cancer metastasis (25).
We found that c-Myc is a target of miR-34a in A498 cells, and
we studied the effect of miR-34a on RhoA activation through the
c-Myc–Skp2–Miz1 transcriptional complex. miR-34a reduced
RhoA expression and overexpression of c-Myc reversed the reduc-
tion of RhoA and inhibition of cell invasion. ChIP assay revealed
that miR-34a suppresses the recruitment of c-Myc to the RhoA
promoter. We demonstrated that miR-34a targets c-Myc and sup-
pressed RhoA transcription by reducing the c-Myc–Skp2–Miz1
transcriptional complex. These data document that miR-34a
suppresses RhoA activation at the initiation of transcription via
targeting c-Myc. Our results also demonstrate that miR-34a
suppresses the assembly and function of the c-Myc complex that
activates RhoA transcription. A schematic model of the mecha-
nisms is shown in Figure 6A and B. Although miR-34a reduced
c-Myc protein expression in 769P cells, RhoA expression was
not significantly suppressed, which suggests that other mechanisms
Fig. 3. miR-34a suppresses the c-Myc transcriptional complex of RhoA.
miR-34a reduces RhoA expression in A498cells. A498cells were
transfected with pre-miR NC or pre-miR-34a for 72 h. (A) RhoA
mRNA level was analyzed by real-time PCR. (B) RhoA protein expression
was analyzed by western blot. (C) c-Myc pulls down endogenous
Miz1, Skp2 and Max in A498 cells. A498 cells were transfected with
pre-miR NC or pre-miR-34a for 72 h and total cell lysates were
immunoprecipitated with c-Myc antibody, followed by western blot
analysis. (D) miR-34a decreases the recruitment of c-Myc to the
RhoA promoter. A498 cells were transfected with pre-miR NC or
pre-miR-34a for 72 h and ChIP assays were performed. P, 0.05 compared
with control.
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prevent reduction of RhoA expression. However, this result
supports the small effect of miR-34a on 769P cell invasion and
RhoA dependence of miR-34a regulation in A498 cell invasion.
The P-TEFb regulates the promoter-proximal pause release
of the elongation phase of transcription by Pol II (26). P-TEFb
is composed of Cyc and Cdk9 (26). c-Myc interacts with CycT1,
the regulatory component of P-TEFb, and regulates the elongation
phase of transcription of Pol II (28–30). P-TEFb is globally in-
volved in the generation of mRNAs and gene expression (30,41)
and is recruited to genes by a variety of transcription fac-
tors (26,42). Our results demonstrate that miR-34a suppresses
the assembly and function of the c-Myc complex that elongates
transcription, which may affect global gene expression. The
miR-34a-induced c-Myc immunocomplex may be heterogeneous
since the ratios of the components were different from those in the
control immunocomplexes. Since miR-34a affects wide variety of
genes besides reducing c-Myc expression, the miR-34a-induced
c-Myc immunocomplex may be heterogeneous.
P-TEFb has been shown to be involved in aberrant transcriptional
elongation in mixed-lineage leukemia (43,44) and various tumor cell
lines overexpress P-TEFb (45). We demonstrated here that miR-34a
inhibits the assembly of the c-Myc–P-TEFb complex presumably by
targeting c-Myc, which is of significance in cancer studies. Our
results suggest that miR-34a suppresses by reducing c-Myc and
affects Pol II pause release in tumor cells, which partly accounts
for its dramatic tumor-suppressing effects. A schematic model of the
mechanisms is shown in Figure 6C and D.
In this study, we show that miR-34a inhibits kidney cancer cell
(A498 and 769P) cell invasion. We also show miR-34a inhibits c-
Myc and its complexes, which we observed in prostate cancer cells
(Yamamura,S, Saini,S, Majid,S, Hirata,H, Ueno,K, Deng,G and Da-
hiya,R, unpublished results). c-Myc activates a variety of genes
through its protein complexes and also regulates transcriptional elon-
gation. We demonstrate here that miR-34a suppresses assembly and
function of the c-Myc–Skp2–Miz1 complex that activates RhoA and
the c-Myc–P-TEFb complex that elongates transcription of various
genes. Therefore, our study reveals a novel role of miR-34a in the
regulation of transcription by c-Myc.
Fig. 4. c-Myc overexpression partially rescues RhoA suppression by miR-34a. (A) A498 cells were transfected with pCMV6-ENTRY only (control) or pCMV6-
ENTRY–c-Myc for 8 h followed by transfection with pre-miR NC or pre-miR-34a for 72 h. Protein level was analyzed by western blot. (B) c-Myc expression
partially rescued inhibition of invasion induced by miR-34a. A498 cells were transfected with pCMV6-ENTRY only (control) or pCMV6-ENTRY–c-Myc for 8 h
followed by transfection with pre-miR NC or pre–miR-34a for 48 h. Cells were harvested and subjected to transwell invasion assay. P , 0.05 compared with
control. (B) Representative images of the invaded cells.
Fig. 5. miR-34a suppresses the c-Myc–P-TEFb complex. (A) A498 or
769P cells were transfected with pre-miR NC or pre–miR-34a for 72 h
and total cell lysates were immunoprecipitated with c-Myc antibody,
followed by western blot analysis. (B) miR-34a suppresses cad expression.
A498 or 769P cells were transfected with pre-miR NC or pre–miR-34a or
pre-miR-con for 72 h. Protein expression level of cad was analyzed by
western blot.
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Supplementary material
Supplementary Figures S1–S6 can be found at http://carcin.
oxfordjournals.org/.
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